Published in Clin Immunol on October 03, 2007
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Low proportions of CD28- CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. J Infect Dis (2014) 1.15
HIV-1 induced bystander apoptosis. Viruses (2012) 1.01
Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis. Cell Mol Life Sci (2008) 1.00
T cell activation but not polyfunctionality after primary HIV infection predicts control of viral load and length of the time without therapy. PLoS One (2012) 0.89
Host and Viral Factors in HIV-Mediated Bystander Apoptosis. Viruses (2017) 0.75
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature (2005) 13.15
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science (1998) 12.81
CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science (1986) 9.17
The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A (1997) 8.27
Immune control of HIV-1 after early treatment of acute infection. Nature (2000) 7.68
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 7.26
Biological and virologic characteristics of primary HIV infection. Ann Intern Med (1998) 5.45
Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 5.30
Acute human immunodeficiency virus type 1 infection. N Engl J Med (1998) 5.04
The relationship between virologic and immunologic responses in AIDS clinical research using mixed-effects varying-coefficient models with measurement error. Biostatistics (2003) 5.00
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42
Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med (2004) 4.37
Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A (2000) 3.66
Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci U S A (2004) 2.57
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A (1997) 2.24
Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol (2002) 2.14
Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med (2003) 2.01
Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS (2004) 1.85
Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis (2000) 1.55
HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res Hum Retroviruses (1996) 1.51
Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection. J Clin Invest (2000) 1.49
Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis (2006) 1.43
Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis (2006) 1.42
Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS (2000) 1.41
Elevated relative fluorescence intensity of CD38 antigen expression on CD8+ T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Cytometry (1996) 1.41
CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses (2004) 1.26
CD8+CD38+ T cells but not HIV type 1 RNA viral load predict CD4+ T cell loss in a predominantly minority female HIV+ adolescent population. AIDS Res Hum Retroviruses (2004) 1.19
Up-regulation of CCR5 and CCR6 on distinct subpopulations of antigen-activated CD4+ T lymphocytes. J Immunol (2002) 1.10
Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infection. Blood (2005) 1.04
Studies on the potential use of CD38 expression as a marker for the efficacy of anti-retroviral therapy in HIV-1-infected patients in Thailand. Virology (2005) 1.00
HIV-1 viral protein R (Vpr) regulates viral replication and cellular proliferation in T cells and monocytoid cells in vitro. J Leukoc Biol (1997) 0.94
Dynamics of cytokine expression in HIV productively infected primary CD4+ T cells. Blood (2004) 0.88
Kinetics of CXCR4 and CCR5 up-regulation and human immunodeficiency virus expansion after antigenic stimulation of primary CD4(+) T lymphocytes. Blood (2000) 0.82
Mature dendritic cells can enhance CD8+ cell noncytotoxic anti-HIV responses: the role of IL-15. Blood (2003) 0.82
CD38 assay may be better predictor of progression. Marker shows how well immune system works. AIDS Alert (1999) 0.77
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep (2009) 11.30
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med (2006) 8.41
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis (2009) 6.17
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis (2011) 4.79
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
Impact of HIV infection and HAART on serum lipids in men. JAMA (2003) 4.01
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol (2002) 3.66
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr (2010) 2.47
The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol (2006) 2.44
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med (2012) 2.40
Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis (2010) 2.37
Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis (2012) 2.36
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis (2011) 2.34
Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J Immunol (2007) 2.30
Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med (2013) 2.29
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis (2011) 2.26
Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis (2006) 2.26
Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis (2004) 2.21
High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis (2009) 2.17
HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model. Retrovirology (2006) 2.17
Whither or wither microbicides? Science (2008) 2.17
Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem (2008) 2.12
Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS (2009) 2.12
Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis (2008) 2.06
Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis (2003) 2.04
Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS (2002) 2.02
Coronary aging in HIV-infected patients. Clin Infect Dis (2009) 2.02
Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med (2002) 1.93
Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood (2012) 1.91
Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One (2011) 1.84
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch Intern Med (2007) 1.84
Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion. Proc Natl Acad Sci U S A (2006) 1.83
Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS (2004) 1.82
Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice. Virology (2008) 1.81
Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol (2010) 1.80
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS (2002) 1.78
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS (2004) 1.74
HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A (2003) 1.71
Interleukin-7-treated naive T cells can be productively infected by T-cell-adapted and primary isolates of human immunodeficiency virus 1. Blood (2002) 1.70
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med (2006) 1.65
The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Stat Med (2012) 1.63
Differential infection patterns of CD4+ T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. Blood (2012) 1.62
Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. Clin Infect Dis (2006) 1.61
Treatment of intestinal worms is associated with decreased HIV plasma viral load. J Acquir Immune Defic Syndr (2002) 1.59
Early immune senescence in HIV disease. Curr HIV/AIDS Rep (2010) 1.58
Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr (2013) 1.57
Clinical validation of the NeuroScreen. J Neurovirol (2005) 1.57
Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis (2010) 1.51
Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States. J Acquir Immune Defic Syndr (2013) 1.50
Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst (2005) 1.50
CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis (2008) 1.49
Reducing the burden of HIV/AIDS in infants: the contribution of improved diagnostics. Nature (2006) 1.48
Viral load testing in resource-limited settings. Clin Infect Dis (2006) 1.47
Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr (2009) 1.46
When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL. Clin Infect Dis (2003) 1.42
Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS (2011) 1.42
Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis (2010) 1.42
Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels. J Infect Dis (2007) 1.42
Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol (2007) 1.41
Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.40
Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma. J Virol (2003) 1.40
Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr (2004) 1.39
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med (2011) 1.37
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS (2005) 1.37
Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr (2007) 1.37
Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection. J Acquir Immune Defic Syndr (2010) 1.36
Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS (2009) 1.35
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets. J Virol (2006) 1.33
Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis (2006) 1.32
Lymphoid follicles are sites of heightened human immunodeficiency virus type 1 (HIV-1) replication and reduced antiretroviral effector mechanisms. AIDS Res Hum Retroviruses (2005) 1.31
Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. J Infect Dis (2006) 1.31
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS (2007) 1.29
CD4 immunophenotyping in HIV infection. Nat Rev Microbiol (2008) 1.27
HLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo. J Virol (2011) 1.26
Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis (2004) 1.21
Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol J (2013) 1.19
Running with scissors: using antiretroviral therapy without monitoring viral load. Clin Infect Dis (2008) 1.19
Incomplete antibody evolution and seroreversion after treatment of primary HIV type 1 infection: what is the clinical significance? Clin Infect Dis (2005) 1.18
Implementation and evaluation of a clinic-based behavioral intervention: positive steps for patients with HIV. AIDS Patient Care STDS (2008) 1.18
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther (2007) 1.17
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis (2007) 1.17